Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Total Lisata Therapeutics, Inc. Stockholders' Equity	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning balance at Dec. 31, 2021	$ 92,000	$ 92,254	$ 4	$ 546,044	$ (70)	$ (453,016)	$ (708)	$ (254)
Common stock, beginning balance (in shares) at Dec. 31, 2021			3,986,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,226)	(4,226)				(4,226)
Share-based compensation (in shares)			49,000
Share-based compensation	593	593		593
Foreign currency translation adjustment	0
Unrealized loss on marketable securities	(126)	(126)			(126)
Common stock, ending balance (in shares) at Mar. 31, 2022			4,035,000
Ending balance at Mar. 31, 2022	88,241	88,495	$ 4	546,637	(196)	(457,242)	(708)	(254)
Beginning balance at Dec. 31, 2022	$ 66,324	66,578	$ 8	574,548	(29)	(507,241)	(708)	(254)
Common stock, beginning balance (in shares) at Dec. 31, 2022	7,866,061		7,867,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (6,187)	(6,187)				(6,187)
Share-based compensation (in shares)			132,000
Share-based compensation	589	589		589
Foreign currency translation adjustment	(12)	(12)			(12)
Unrealized loss on marketable securities	$ (11)	(11)			(11)
Common stock, ending balance (in shares) at Mar. 31, 2023	7,998,342		7,999,000
Ending balance at Mar. 31, 2023	$ 60,703	$ 60,957	$ 8	$ 575,137	$ (52)	$ (513,428)	$ (708)	$ (254)